Neurodevelopmental Disorders
24 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Mental Disorders
Narrower: Asperger Syndrome 1, Attention Deficit Disorder with Hyperactivity 8, Autism Spectrum Disorder 14, Autistic Disorder 5, Schizophrenia, Childhood 1
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Academic Competency Enhancement (ACE) classroom for attention deficit disorder with hyperactivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Arbaclofen for autism spectrum disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bexicaserin for neurodevelopmental disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation for autistic disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EB-1020 (Centanafadine) high dose for attention deficit disorder with hyperactivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| EB-1020 (Centanafadine) low dose for attention deficit disorder with hyperactivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Esomeprazole for autistic disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbiota Transplant (FMT) for attention deficit disorder with hyperactivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fecal Microbiota Transplant (FMT) + Vancomycin + NITAZOXANIDE for attention deficit disorder with hyperactivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| hUC-MSC-Exos Nasal Spray for autism spectrum disorder | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| KarX-EC + KarXT for autism spectrum disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| KarX-EC + KarXT for autistic disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| KarXT for autistic disorder | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Leucovorin for asperger syndrome | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Leucovorin for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Leucovorin for autistic disorder | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Levoleucovorin calcium for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Lysergide d-tartrate for attention deficit disorder with hyperactivity | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Navigate for schizophrenia, childhood | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Oxytocin for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Saccharomyces cerevisiae for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| TTYP01 Tablets (12mg or 18mg) for autism spectrum disorder | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vancomycin + NITAZOXANIDE for attention deficit disorder with hyperactivity | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Viloxazine hydrochloride for attention deficit disorder with hyperactivity | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 5 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.